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Lyme disease is a complex immune-mediated multi-system disorder that is infectious in
origin and inflammatory or "rheumatic" in expression. Through its epidemiologic character-
istics, large numbers of a seasonally synchronized patient population are readily available for
prospective study. Lyme disease has a known clinical onset ("zero time"), marked by the
characteristic expanding skin lesion, erythema chronicum migrans, and a clearly defined pre-
articular phase. At least some manifestations ofthe disorder are responsive to antibiotics, and
the causative agent-a spirochete-is now known. These advantages make Lyme disease
unique as a human model for an infectious etiology of rheumatic disease.
Lyme disease (formerly Lyme arthritis) was recognized in November 1975 because
of unusual geographic clustering of children with inflammatory arthropathy in the
region ofLyme, Connecticut [1]. It is now known to be acomplex immune-mediated
multi-system disorder occurring at any age, in either sex, with onset in summer or
early fall. Its clinical hallmark is an early expanding skin lesion, erythema
chronicum migrans (ECM), which may be followed weeks to months later by
neurologic, cardiac, orjoint abnormalities [2-7]. Symptoms mayrefer to any one of
these four systems alone or in combination. Foci of Lyme disease have been found
elsewhere along the northeastern coast ofthe United States, in many other states, in
Europe, and in Australia. The disease is caused by a newly recognized spirochete
[8-10], and transmitted primarily by the minute tick Ixodes dammini or by related
ixodid ticks [11-13J].
Since our earliest work on Lyme disease, we have always looked beyond it, for
possible insights into the onset and development of other inflammatory immune-
mediated, "rheumatic" diseases. Here we shall consider for comparison rheumatoid
arthritis, the most prevalent example ofthis constellation of disorders. As a human
model for an infectious etiology ofrheumatic disease, Lyme disease has distinct ad-
vantages, of which some ofthe more important ones (Table 1) form the core ofthis
discussion.
The seasonal onset, in summer or early fall, provided a synchronized patient
population and allowed us to "tool up" for each new outbreak, for whatever study
seemed most attractive at the time. The closeness ofthe Lyme region to our group in
New Haven helped make effective a surveillance network. For the epidemiology of
473
Address reprint requests to: Stephen E. Malawista, M.D., Dept. of Internal Medicine, Section of
Rheumatology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510
Copyright t 1984 by the Yale Journal of Biology and Medicine, Inc.
All rights of reproduction in any form reserved.MALAWISTA ET AL.
TABLE 1
Lyme Disease: Advantages as a Human Model
for an Infectious Etiology of Rheumatic Disease
1. Seasonal onset: Summer, early fall
2. Accessible population: in our "backyard"
3. Adequate case numbers: now
- 100 per season
4. Known clinical onset of disease ("zero time"):
Erythema chronicum migrans
5. Pre-articular phase:
Development of the immune response
Immunogenetic determinants
6. Responsiveness to penicillin
7. Known causative agent: Spirochete
Lyme disease, this seasonal and geographic clustering suggested an infectious
etiology, and the presence of adequate numbers of patients allowed a hit-or-miss
pattern of affected individuals to be seen in a given season, a pattern compatible
with a suspected arthropod-borne vector. Adequate numbers of cases also permitted
the recognition of subgroups of Lyme disease and resulted in the appearance of
families containing affected and non-affected individuals over as many as three
generations-an ideal presentation for immunogenetic analysis.
In the study of Lyme disease, erythema chronicum migrans (ECM) has had many
roles. It quickly became the most definitive diagnostic sign [2,7]. From its ap-
pearance, and from patient histories, epidemiologic studies, and a long European
experience with ECM, we were led backward rather quickly to the tick vector
[11-13], now called Ixodes dammini [14], and eventually to the causative spirochete
[8-10]. Most important for experimental work, erythema chronicum migrans marks
the clinical onset of disease, the "zero time" so important for proper retrospective
and especially prospective studies [15].
Together with its establishment of clinical onset, erythema chronicum migrans
marks a pre-articular phase of Lyme disease. This advantage manifested itself in
several ways. It allowed a spectrum of clinical subgroups to be established. At one
extreme were those with mild disease, consisting of erythema chronicum migrans
that healed without sequelae. At the other extreme were patients with severe disease
having subsequent neurologic or chronic joint involvement. We could therefore
compare not only affected individuals with controls, but subgroups ofpatients with
each other. Subgroups were found to differ in their humoral immune response
[16,17]: those with elevated serum IgM and cryoglobulins containing IgM at thetime
of ECM were likely to develop subsequent severe disease; those without these find-
ings were not. In other words, the early humoral findings had prognostic significance.
In immunogenetic studies [4,18], severe disease and elevated serum IgM cor-
related with the presence ofthe B-cell alloantigen DR2. Rearranged into what would
appear to be their proper order, these findings seem to exemplify a situation in
which an individual's immunogenetic make-up determines the variety ofhis immune
response to infection, which in turn determines the clinical expression of disease.
A key question in rheumatoid arthritis is when and how it begins. Without a
reliable zero time or pre-articular phase, the diagnosis can only be made when ar-
thritis is well established. In our model, erythema chronicum migrans and the
474LYME DISEASE: UNIQUE HUMAN RHEUMATIC DISEASE MODEL
known tick vector, Ixodesdammini, have provided answers to when and how: infec-
tion begins with the tick bite; erythema chronicum migrans appears three to 32 days
later; and arthritis, when it occurs, begins weeks (or up to two years) after ECM [7].
The afflicted joint may be pathologically indistinguishable from one affected by
rheumatoid arthritis, even to the extent of pannus formation and erosion of car-
tilage and bone [2,4,6]. Thus, the model demonstrates that this final common
pathway of joint pathology-this "rheumatoid" lesion-can occur within a matter
of months.
The well-defined zero time and pi-e-articular phase also allowed us to trace the im-
munologic evolution of Lyme disease, long before an etiologic agent had been iden-
tified. By the time erythema chronicum migrans appears, almost all patients have
abnormal serum Clq-binding activity, a measure of circulating immune complexes
[19,20]. The abnormal binding persists in patients with subsequent nerve or heart in-
volvement, but usually disappears within three months among those with only
subsequent arthritis. In the synovial fluid of affected joints, however, abnormal
binding is uniformly present, and always to a greater extent than in the circulation.
(Again, in rheumatoid arthritis, it is not until this apparently late date in the natural
history of the disorder that we arrive upon the scene.) And adjacent to that fluid is
proliferative synovium often replete with lymphocytes and plasma cells that, as in
rheumatoid arthritis [21], are presumably capable of producing immunoglobulin
locally. Thus our model seems to portray an initially disseminated, immune-
mediated inflammatory disorder that in some patients becomes localized and prop-
agated in joints.
The nextmajoradvantageofthis humanmodelis its responsiveness to antibiotics,
andparticularly to penicillin. Ourinitialexperiencewith oral antibiotics did not con-
firm European suggestions that penicillin or tetracycline cures erythema chronicum
migrans, a lesion that often resolves promptly even without treatment. As the
number ofpatients increased (again, the advantage ofadequate numbers), itbecame
clear that these drugs do shorten the duration of ECM and prevent or attenuate
subsequent disease [22,23]. The clear implication, since confirmed [9], was that a
penicillin- (and tetracycline)-sensitive agent is often still present at this stage of the
illness.
This finding ruled out a viral etiology, and narrowed the possible contenders to a
list on which some kind of spirochete was most likely. It also provided a general
method of approaching the question whether the host is still harboring a live
causative agent at a given stage of disease: if penicillin cures the disease, then the
agent was there. (Note that only this positive result is decisive; failureto cureis more
ambiguous.) And penicillin in particular can be used in high parenteral dosage with
relative impunity. Indeed, we have now cured Lyme meningitis with penicillin [24]
(and the causative agent has been cultured from cerebrospinal fluid [9]). We are well
aware of the rheumatologic implications of a disorder (Lyme meningitis) formerly
treated with high-dose corticosteroids tapered over months [3], now cured by high-
dose penicillin in days [22]. Formerly, we suppressed the host's response to an agent
that is immunostimulatory but otherwise apparently rather unaggressive; now (with
antibiotics) we address the agent directly.
We are currently evaluating the effect ofhigh-dose penicillin on established Lyme
arthritis. The question whether a persistent infectious agent is necessary for con-
tinued disease activity (versus the persistence ofantigenic degradation products; the
periodic rechallenge ofultimately injurious immunologic memory cells; or the trig-
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gering of true self-perpetuating autoimmunity) is ofcentral importance in a number
of immune-mediated disorders.'
The final major advantage ofthis model is its known causative agent, the L dam-
mini spirochete. Specific antigen is what every rheumatologist dreams of having at
his disposal; a whole organism is even better. It opens up entirely new areas of
endeavor; for example, diagnosis through the use of specific antibody [8-10];
localization ofthe organism [25,27] (or parts ofit, or cross-reacting components) in
tissues; the antigen-specific immunology of the disease; the establishment of
prevalence in vectors [8-10], and of true attack rates in human and animal hosts;
and the development of animal models.
In summary, as a model for an infectious etiology ofrheumatic disease (Table 1),
Lyme disease, a human, immune-mediated inflammatory disorder, has intrinsic ad-
vantages which, taken together, areunique. We suspect that this model will continue
to be useful in helping us to consider thepossible evolution ofother rheumatic prob-
lems whose developmental signposts are less prominent or lacking.
'Noteaddedinproof: Since this paper was written, we havepresented evidence that Lymearthritis may
be treated successfully with high-dose parenteral penicillin [26]. Moreover, spirochetes have been found
in synovial lesions of Lyme arthritis [27].
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